Archive | 2009-2012 Life Science Portfolios

J.P.Morgan Conference #2: Red Screen Distracts Biotech Investors…Update

Green Screen Alert Market Update…IBB up 4% today erasing most of Wednesday’s Losses but we are still down 13.86% for the five day period. Nasdaq rallied 1.97%. Rayno Biopharma top winners: ABBV up 6.56%, ALXN up 5.93%, AMGN up 5.29%,BIIB up 4.98%, REGN up 4.25%,RXDX up 8.96%, SGEN up 2.26% and VRTX up 5.75%. Most […]

Continue Reading 0

J.P.Morgan Healthcare Conference #1: Investors Move into Life Science Stocks-Bouncing off the Bottom

J.P.Morgan Conference: Relief Rally in Life Science Stocks After Rough Start to 2016 Green screen day with improved macro and healthcare sector leading Who knew biotech stocks traded with energy? Over the next few days we will review themes and companies from presentations at the 34th Annual J.P.Morgan Healthcare Conference. Our initial focus will be […]

Continue Reading 0

Biotech Rally Gains Momentum…Update-1

Update-1 Rayno Recap for week of 11/20/15 IBB up 3.04%, XBI  up 1.92%,  XLV up 2.82% Notable Small Cap Winners Curis (CRIS) up 4.13%, Fibrocell Sciences (FCSC) up 3.42%, Geron (GERN) up 4.82%, Ignyta (RXDX) up 37.39%, and Ocera Therapeutics (OCRX) up 5.31%. Notable Rayno Dx and Tools Winners Cepheid (CPHD) up 6.45%, Illumina (ILMN) […]

Continue Reading 0

Rayno Life Science Stocks: Be An Investor Not A Trader…Update-1

Update-1 …After 1.94% NASDAQ Sell-Off All three market indices got crushed today with a downdraft attributed to ending of QE, rising i rates in 2015, a rising dollar and just plain profit taking. A 3.8% hit on Apple (AAPL) did not help support the QQQ which also holds many large cap biotech stocks.The healthcare sector […]

Continue Reading 0

FED Finesse-Steady As She Goes-Large Cap Biotechs Near Highs Update -1 PBYI

Taper Lite With Zero Interest Rates The big FED Meeting with the Bernanke farewell concluded with “taper lite”, optimism on the economy and continued low inflation. The FED decision to roll back its economic stimulus was welcomed by investors boosting the S&P by 1.7% to a record 1810 and NASDAQ up 1.2%. Low interest rate […]

Continue Reading 0

Fidelity Select Biotechnology Fund (FBIOX) Outperforms Biotech ETFs YTD

Life Science Sector at or Near YTD and All Time Highs Fidelity Fund (FBIOX) Outperform ETFs Over the past 3 years we reviewed how ETFs complement a biotechnology  investment strategy and compared three of the largest and most liquid : FBT, IBB and XBI (see the articles below and our comprehensive article from May 2011). […]

Continue Reading 0

Politics Curb Further Market Gains-Short Term Caution

No matter what your political persuasion you should know that your dysfunctional government may weaken the economy and damage your portfolio. Jim McTague in his Sep 23 Barron’s column, The GOP’s Threat to Investors, provides the scenario whereby he says…” Ben Bernanke never underestimates the ability of Congress to blow up the economy. Neither should […]

Continue Reading 0

Money Talks, Stocks Run, Don’t Walk and Biotech is Up 1.4% Update 1 ASTX up 23%

M&A Moves Down the Food Chain: Otsuka to Buy Astex for ~$900M Astex Pharmaceuticals (ASTX $8.22) has been on our focus list since 12/27/11 at $1.63 and today the stock is up 23% on buy-out news as Otsuka seeks cancer drug pipeline. Coming soon, a comparison of mid-cap biopharma stocks. Astex (ASTX) is the 7th Company […]

Continue Reading 0

Biotech Funds and ETFS:JNGLX,FBDIX,FBIOX

See This Week’s issue of Barron’s (JY 15 p 31)  for a good  summary of the  biotech sector.  See also our article at bottom of page from Investor Uprising in 2011.We have covered many ETFs and funds over the years and have favored Fidelity Select Biotechnology Fund (FBIOX) and ETFs such as IBB and XBI. […]

Continue Reading 0

Biotech Stocks MOve Up Today for Impressive Q1 Performance: BIIB,IBB,GILD,REGN

Rayno Life Science Stocks Having A Nice Q1 Ending Run Well known Large Caps Dominate Rayno focus stocks that are running up 2% + today: AMGN, AMRI, ASTX, BIIB, GILD, QGEN, and REGN.  The Biopharma sector is outperforming Tools and Dx for Q1.   Tools and DX winners for the week are ALR, ILMN, and […]

Continue Reading 0

Life Science Stocks Look Toppy: Red Screen Today ALXN,IBB,REGN Update 1

Raise a Little Cash as Macro Focus Brings Choppy Action Life Science stocks took a hit today underperforming NASDAQ which was down only 3.35 pts. The biotech sector has been pretty much on a tear since the November bottom as they re-accelerated in mid-December. The biotech ETF (IBB) shows a double top from October and […]

Continue Reading 0

Who Knows About the Bull Market in Biotech Stocks?

Is There No End to the Biotech Bull Market? Biotech ETFs NASDAQ Biotechnology (IBB) up 36% YTD and NYSE (FBT) up 42% YTD Around 1998 I remember vividly two market conversations: one from a Sun Micro sales executive telling me “there is no end to chip stocks”; the other from an astute investor telling a […]

Continue Reading 0

Rayno Life Science Portfolio: AMGN, EXAS, NEOG, REGN Winners on a Risk-Off Day

Biotech Stocks Remain Resilient On A Bad Day The market took a nasty turn today with a 1.36% sell-off in NASDAQ and 1.05% for the S&P. The damage was across the board but the healthcare sector rose above the flack down only 0.11%. Large cap drug and biopharmaceutical stocks were green. Our mid-cap biopharma index […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science Update-Macro Rules, Risk Off

Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off  down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD […]

Continue Reading 0